Pancreatic Cancer Research

ResearcherUniversity of Campania "Luigi Vanvitelli"Active in the last 2 years

Fortunato Ciardiello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3369-4841; OpenAlex author ID A5056034569. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 8

  1. Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case Report and Literature Review. Co-author DOI 10.3390/ijms27135722↗
  2. Targeting the Tumor-Stroma Crosstalk: An AI-Based Virtual Screening Strategy for Dual MET/SMO Inhibitors in Pancreatic Cancer Co-author DOI 10.64898/2026.07.03.736313↗
  3. Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16040824↗
  4. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Co-author DOI 10.1007/s12032-019-1306-9↗
  5. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… First author DOI 10.1016/j.ctrv.2016.09.001↗
  6. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. Co-author DOI 10.1186/s12885-016-2671-9↗
  7. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and liter… Co-author DOI 10.3892/ol.2016.5279↗
  8. Targeting EGFR in pancreatic cancer treatment. Last author DOI 10.2174/138945012800564158↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ferdinando De Vita · 5 shared papers, 2016–2026 · strength 0.64
  2. Chiara Carmen Miceli · 2 shared papers, 2024–2026 · strength 0.46
  3. Floriana Morgillo · 3 shared papers, 2012–2026 · strength 0.33
  4. Rosaria Benedetti · 1 shared paper, 2026 · strength 0.24
  5. Stefania Scala · 1 shared paper, 2026 · strength 0.24
  6. Sandro Cosconati · 1 shared paper, 2026 · strength 0.24
  7. Crescenzo D’Alterio · 1 shared paper, 2026 · strength 0.24
  8. Ugo Chianese · 1 shared paper, 2026 · strength 0.24
  9. Michele Roggia · 1 shared paper, 2026 · strength 0.24
  10. Luca Pompella · 2 shared papers, 2019–2024 · strength 0.24
  11. Michele Orditura · 3 shared papers, 2012–2019 · strength 0.17
  12. Carlo Caputo · 1 shared paper, 2024 · strength 0.16
  13. Alessandro Ottaiano · 1 shared paper, 2024 · strength 0.16
  14. Donatella Coradduzza · 1 shared paper, 2024 · strength 0.16
  15. Michele Caraglia · 1 shared paper, 2024 · strength 0.16
  16. Gabriella Misso · 1 shared paper, 2024 · strength 0.16
  17. Angelica Petrillo · 2 shared papers, 2016–2019 · strength 0.13
  18. Teresa Troiani · 2 shared papers, 2012–2016 · strength 0.08
  19. Annalisa Pappalardo · 1 shared paper, 2019 · strength 0.08
  20. Floris A. de Jong · 1 shared paper, 2016 · strength 0.06
  21. Jean‐Frédéric Blanc · 1 shared paper, 2016 · strength 0.06
  22. Arndt Vogel · 1 shared paper, 2016 · strength 0.06
  23. Sharlene Gill · 1 shared paper, 2016 · strength 0.06
  24. Alfredo Carrato · 1 shared paper, 2016 · strength 0.06
  25. Richard A Hubner · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.